Julie VanOrsdel Daves - Sep 13, 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: SVP Clinical Development Oper.
Signature: /s/ Amy Culbert, attorney-in-fact
Stock symbol: DMAC
Transactions as of: Sep 13, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/15/2022, 04:41 PM
Next filing: Jun 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						0	Sep 13, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+140K		$0.00	140K	Sep 13, 2022	Common Shares	140K	$1.47	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option vests with respect to 35,000 common shares on September 13, 2023 and with respect to the remaining 75% of the common shares in 36 nearly equal monthly installments commencing one month after the one-year anniversary of the grant date.